IDEAYA Biosciences (NASDAQ:IDYA) vs. Codexis (NASDAQ:CDXS) Financial Survey

IDEAYA Biosciences (NASDAQ:IDYA) and Codexis (NASDAQ:CDXS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Institutional & Insider Ownership

98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 2.5% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 1.9% of Codexis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares IDEAYA Biosciences and Codexis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-31.42%	-29.45%
Codexis	-113.67%	-105.83%	-46.06%

Analyst Recommendations

This is a summary of recent recommendations and price targets for IDEAYA Biosciences and Codexis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	0	3	10	0	2.77
Codexis	0	1	1	0	2.50

IDEAYA Biosciences currently has a consensus target price of $48.0909, indicating a potential upside of 99.96%. Codexis has a consensus target price of $11.00, indicating a potential upside of 283.28%. Given Codexis’ higher probable upside, analysts plainly believe Codexis is more favorable than IDEAYA Biosciences.

Volatility & Risk

IDEAYA Biosciences has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Comparatively, Codexis has a beta of 2.54, meaning that its share price is 154% more volatile than the S&P 500.

Earnings & Valuation

This table compares IDEAYA Biosciences and Codexis”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$7.00 million	301.11	-$274.48 million	($3.79)	-6.35
Codexis	$59.35 million	4.37	-$65.28 million	($0.83)	-3.46

Codexis has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Summary

IDEAYA Biosciences beats Codexis on 8 of the 14 factors compared between the two stocks.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

About Codexis

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.